Chronic Kidney Disease (CKD), which ... are a critical part of successful outreach. The Kidney Disease: Improving Global Outcomes (KDIGO) heat map, produced by an international group of ...
There’s also MZE782, an oral SCL6A19 inhibitor in a phase 1 trial with healthy volunteers and plans to pursue the drug in chronic kidney disease and phenylketonuria. From these raises ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback